Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-MS-1467 in Relapsing Multiple Sclerosis
NCT01973491Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2014
- Primary completion
- Apr 2016
- Modality
- Peptides, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ATX-MS-1467 in multiple sclerosis (MS), sponsored by Merck KGaA. Started Feb 2014; status: completed.
02
Drugs
ATX-MS-1467
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01973491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01973491.